ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Roche has agreed to acquire Poseida Therapeutics, a chimeric antigen receptor T-cell (CAR-T) therapy company based in San Diego, for about $1.5 billion. Roche and Poseida already have a partnership to develop therapies for hematologic cancers; the purchase will add Poseida’s solid- tumor and autoimmune programs and genetic engineering platform. Poseida has three CAR-T candidates in Phase 1 trials. In partnership with Roche, it has one candidate for B-cell malignancies and one for multiple myeloma; separate from Roche, it has a candidate for solid tumors in breast, ovarian, renal, colorectal, lung, and pancreatic cancers.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X